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Authors’ reply
The results from our randomised 
phase 3 trial1 showed that young 
patients, affected by high-risk diffuse 
large B-cell lymphoma (age-adjusted 
International Prognostic Index score 
of 2–3), who received abbreviated 
rituximab-dose-dense chemotherapy 
plus high dose therapy and autologous 
stem-cell transplantation compared 
with patients who received full course 
rituximab-dose-dense chemotherapy 
had an improvement in failure-free 
survival, but not in overall survival.
Tetsuya Tanimoto and colleagues 
commented that the presence of more 
than one extranodal site of disease 
might affect the prognosis in young 
patients with untreated high-risk 
diffuse large B-cell lymphoma and 
treated in the rituximab-era.2
In our study,1 involving 399 patients 
younger than 60 years, 127 (32%) 
patients had a number of extranodal 
sites that were more than one at 
diagnosis, equally distributed into 
the four randomisation arms (32% 
in each group). At the end of the 
treatment, 208 (76%) of 272 patients 
with no or one extranodal site of 
disease achieved a complete response 
compared with 87 (69%) of 127 with 
more than one extranodal localisation.
In our analysis, patients with more 
than one extranodal site of disease 
showed reduced failure-free survival 
and overall survival compared with 
those with no or one extranodal site 
during the first year of observation, 
but differences disappeared 
progressively over time (appendix). 
The failure-free survival at 2 years 
was 66% (95% CI 60–72) for those 
with more than one extranodal site 
compared with 66% (57–74) for 
those with no or one extranodal site 
(log-rank test p=0·87). The overall 
survival at 5 years was 76% (95% 
CI 67–82) for those with more than 
one extranodal site compared with 
78% (72–83) for those with no or one 
extranodal site (log-rank test p=0·42). 
In conclusion, in our randomised 
phase 3 trial, the number of extranodal 
sites of disease did not influence the 
outcome of young patients with high-
risk diffuse large B-cell lymphoma 
with poor prognosis.
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